Vidman Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -67.65%
(FY 2023)
- Profit -94.97%
(FY 2023)
- Ebitda -19.44%
(FY 2023)
- Net Worth 1.10%
(FY 2023)
- Total Assets -10.83%
(FY 2023)
About Vidman Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhavesh Bhavsar, Aashay Patel, Mohammadriyaz Panara, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24110GJ2017PTC098605
- Company No.
098605
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 2017
- Date of AGM
23 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Vidman Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhavesh Bhavsar  | Director | 18-Nov-2017 | Current |
| Aashay Patel | Director | 05-Aug-2019 | Current |
| Mohammadriyaz Panara | Director | 21-Jan-2020 | Current |
| Mittalkumar Patel | Director | 05-Aug-2019 | Current |
| Rajeshkumar Gami | Director | 07-Aug-2017 | Current |
Financial Performance of Vidman Pharmaceuticals.
Vidman Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 67.65% decrease. The company also saw a substantial fall in profitability, with a 94.97% decrease in profit. The company's net worth moved up by a moderate rise of 1.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vidman Pharmaceuticals?
In 2023, Vidman Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Brichem Sciences Private LimitedActive 8 years 17 daysAashay Patel, Mittalkumar Patel and 1 more are mutual person
Maharshi Pharma Chem Private LimitedActive 26 years 3 monthsAashay Patel and Mittalkumar Patel are mutual person
- Someshwar Ispat Private LimitedActive 15 years 4 months
Aashay Patel and Mittalkumar Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vidman Pharmaceuticals?
Vidman Pharmaceuticals has a workforce of 15 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vidman Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vidman Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
